Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

ALK +
- EGFR/HER2 Mutation, Untreated CNS Mets
  - VAR0092 Phase I First-in-Human Dose-Escalation/ Safety/ Tolerability/ Pharmacokinetics of X-396 in Solid Tumors
    PI: Wakelee Xcovery
  - LUN0082 Phase II/III Anti-Tumor Activity of Oral EGFR/HER2 Inhibitor AP23788 in Non-Small Cell Lung Cancer
    PI: Neal Aridus Pharmaceuticals
- KRAS+
  - LUN097 Phase II Regorafenib in Combo w/ Oral Methotrexate in KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
    PI: Padda Stanford
  - LUN095 Phase II/III TKI 1st/2nd Generation
    PI: Wakelee ACEA Bioscience
  - LUN0083 Phase IIII AC0010MA Previously Treated EGFRmut & Acquired T790M Mutation NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance
    PI: Wakelee ACEA Bioscience
- KRAS−
  - Failed EGFR or ALK Inhibitor
  - Falled EGF/ Resistant to TK1 inhibitors
    PI: Padda EpigenRx, Inc
  - LUN084 Phase II RRx-001 in SCLC / NSCLC / Neuroendocrine Carcinoma or Ovarian Cancer (Including MMTC)
    PI: Neal Adapimmune Ltd
- Mesothelin +
  - VAR0155 Phase Ia Anetumab Ravtansine (BAY 94-9363) in Mesothelin-Expressing Advanced/ Recurrent/ Malignancies
    PI: Padda Bayer
  - LUN078 Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies
    PI: Neal Adapimmune Ltd
  - MAGE-A10
    PI: Neal Adapimmune Ltd

LUN080-CCT5004 VII
  - MAGE-A10c79T in Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
    PI: Neal Adapimmune Ltd